Seeking Alpha
21 Aug 2026, 20:48 UTC · 2h ago
ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
21 Aug 2026, 20:48 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ProQR's AX-0810 achieved an 8-fold increase in serum bile acids during phase 1, significantly exceeding the 2-fold target. — Strong proof-of-concept data for a disease-modifying therapy in biliary atresia suggests high clinical efficacy and a higher probability of regulatory success.
+0.80Full phase 1 data for AX-0810 and phase 1 data for next-gen AX-0811 are expected by the end of 2026. — Clear clinical catalysts provide specific time-bound milestones that can drive stock volatility and valuation updates.
+0.40Pediatric biliary atresia data from China is expected in the first half of 2027. — Expansion into pediatric populations and the Chinese market represents significant potential growth in the total addressable market.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The analyst initiated a Buy rating based on strong human proof-of-concept and positive phase 1 results for its RNA editing platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
14h ago
